3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[2]  Rachel L. Mistur,et al.  Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal , 2010, Neurobiology of Aging.

[3]  Michael Weiner,et al.  Automated 3d Mapping of Baseline and 12-month Associations between Three Verbal Memory Measures and Hippocampal Atrophy in 490 Adni Subjects and the Alzheimer's Disease Neuroimaging Initiative , 2022 .

[4]  D. Head,et al.  Amyloid Plaques Disrupt Resting State Default Mode Network Connectivity in Cognitively Normal Elderly , 2010, Biological Psychiatry.

[5]  Maximilian Reiser,et al.  White matter microstructure underlying default mode network connectivity in the human brain , 2010, NeuroImage.

[6]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[7]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2010, Neurology.

[8]  A. Fagan,et al.  APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.

[9]  Liana G. Apostolova,et al.  Comparison of AdaBoost and Support Vector Machines for Detecting Alzheimer's Disease Through Automated Hippocampal Segmentation , 2010, IEEE Transactions on Medical Imaging.

[10]  W. M. van der Flier,et al.  Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment , 2009, Neurology.

[11]  G. Alexander,et al.  Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. , 2009, The New England journal of medicine.

[12]  A. Fagan,et al.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.

[13]  Mark A Mintun,et al.  Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. , 2009, Archives of neurology.

[14]  Michael Schaefer,et al.  Distinct brain networks in recognition memory share a defined region in the precuneus , 2009, The European journal of neuroscience.

[15]  Nick C Fox,et al.  Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease , 2009, Neurology.

[16]  Amity E. Green,et al.  Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls , 2009, Human brain mapping.

[17]  Nick C Fox,et al.  Conversion of amyloid positive and negative MCI to AD over 3 years , 2009, Neurology.

[18]  A. Levey,et al.  Is ApoE &egr;4 Associated with Cognitive Functioning in African Americans Diagnosed with Alzheimer Disease? An Exploratory Study , 2009, Southern medical journal.

[19]  J. Cummings.  Defining and labeling disease-modifying treatments for Alzheimer's disease , 2009, Alzheimer's & Dementia.

[20]  M. Sarazin,et al.  Faculty Opinions recommendation of Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. , 2009 .

[21]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[22]  Magda Tsolaki,et al.  Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study , 2009, The Lancet Neurology.

[23]  G. Frisoni,et al.  Markers of Alzheimer's disease in a population attending a memory clinic , 2009, Alzheimer's & Dementia.

[24]  M. Weiner,et al.  Selective effect of age, Apo e4, and Alzheimer's disease on hippocampal subfields , 2009, Hippocampus.

[25]  K. Blennow,et al.  Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment , 2009, Neurobiology of Aging.

[26]  Cindee M. Madison,et al.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.

[27]  G. Frisoni,et al.  In vivo mapping of amyloid toxicity in Alzheimer disease , 2009, Neurology.

[28]  V. Libri,et al.  Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies , 2009, Journal of neurochemistry.

[29]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[30]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[31]  Norbert Schuff,et al.  Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls , 2009, NeuroImage.

[32]  A. Fagan,et al.  Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly , 2009, Annals of neurology.

[33]  E. Sinforiani,et al.  Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer’s disease and vascular dementia , 2008, Neurological Sciences.

[34]  Michael Weiner,et al.  and the Alzheimer’s Disease Neuroimaging Initiative* , 2007 .

[35]  Liana G. Apostolova,et al.  Automatic Subcortical Segmentation Using a Contextual Model , 2008, MICCAI.

[36]  Norbert Schuff,et al.  Selective effect of Apo e4 on CA3 and dentate in normal aging and Alzheimer's disease using high resolution MRI at 4 T , 2008, NeuroImage.

[37]  J. Brandt,et al.  APOE ε4 allele predicts faster cognitive decline in mild Alzheimer disease , 2008, Neurology.

[38]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[39]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[40]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[41]  C. Jack,et al.  11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment , 2008 .

[42]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[43]  Nick C Fox,et al.  Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment , 2007, Neurology.

[44]  W. Klunk,et al.  Impact of amyloid imaging on drug development in Alzheimer's disease. , 2007, Nuclear medicine and biology.

[45]  M. Viitanen,et al.  PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment , 2007, Neurology.

[46]  Paul Maruff,et al.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.

[47]  P. Thompson,et al.  PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.

[48]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[49]  Kiralee M. Hayashi,et al.  3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease. , 2006, Brain : a journal of neurology.

[50]  Lisa A. Weissfeld,et al.  Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease , 2006, NeuroImage.

[51]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[52]  Norbert Schuff,et al.  Longitudinal stability of MRI for mapping brain change using tensor-based morphometry , 2006, NeuroImage.

[53]  E. Tangalos,et al.  Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. , 2006, Archives of neurology.

[54]  Kiralee M. Hayashi,et al.  Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. , 2006, Archives of neurology.

[55]  Anders M. Dale,et al.  Reliability in multi-site structural MRI studies: Effects of gradient non-linearity correction on phantom and human data , 2006, NeuroImage.

[56]  B. Reisberg,et al.  Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment , 2006, Neurobiology of Aging.

[57]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[58]  K. Blennow,et al.  CSF Biomarkers for Alzheimer’s Disease: Levels of β-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival , 2006, Dementia and Geriatric Cognitive Disorders.

[59]  Yvette I. Sheline,et al.  Potential antecedent marker of Alzheimer disease , 2006 .

[60]  Norbert Schuff,et al.  Validation Testing of the MRI Calibration Phantom for the Alzheimer's Disease Neuroimaging Initiative Study , 2006 .

[61]  K. Blennow,et al.  Phosphorylated tau predicts rate of cognitive decline in MCI subjects: A comparative CSF study , 2005, Neurology.

[62]  John D E Gabrieli,et al.  Implicit memory and Alzheimer's disease neuropathology. , 2005, Brain : a journal of neurology.

[63]  Benjamin J. Shannon,et al.  Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.

[64]  Charles DeCarli,et al.  Sex, Apolipoprotein E ε4 Status, and Hippocampal Volume in Mild Cognitive Impairment , 2005 .

[65]  M. Weiner,et al.  Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia , 2005, Annals of neurology.

[66]  Alan C. Evans,et al.  Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. , 2005, Archives of neurology.

[67]  K. Kiehl,et al.  A supramodal limbic‐paralimbic‐neocortical network supports goal‐directed stimulus processing , 2005, Human brain mapping.

[68]  Charles DeCarli,et al.  Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. , 2005, Archives of neurology.

[69]  Vladimir V. Frolkis,et al.  Neurobiology of Aging , 2019, Psychobiology of Behaviour.

[70]  Alan A. Wilson,et al.  A rapid one-step radiosynthesis of the β-amyloid imaging radiotracer N-methyl-[11C]2-(4′-methylaminophenyl)-6-hydroxybenzothiazole ([11C]-6-OH-BTA-1) , 2004 .

[71]  H. Möller,et al.  Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment , 2004, Molecular Psychiatry.

[72]  T. Ohm,et al.  Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology , 2004, Neurobiology of Aging.

[73]  W. Markesbery,et al.  Delayed recall, hippocampal volume and Alzheimer neuropathology , 2004, Neurology.

[74]  H. Möller,et al.  Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. , 2004, Molecular psychiatry.

[75]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[76]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[77]  A Drzezga,et al.  Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. , 2002, Archives of neurology.

[78]  H. Arai,et al.  CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects , 2002, Neurology.

[79]  G. Aguirre,et al.  Experimental Design and the Relative Sensitivity of BOLD and Perfusion fMRI , 2002, NeuroImage.

[80]  A. Dale,et al.  Whole Brain Segmentation Automated Labeling of Neuroanatomical Structures in the Human Brain , 2002, Neuron.

[81]  L. Beckett,et al.  Annual Incidence of Alzheimer Disease in the United States Projected to the Years 2000 Through 2050 , 2001, Alzheimer disease and associated disorders.

[82]  J Mazziotta,et al.  A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[83]  K. Blennow,et al.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.

[84]  C. Jack,et al.  Rates of hippocampal atrophy correlate with change in clinical status in aging and AD , 2000, Neurology.

[85]  D A Bennett,et al.  Hemispheric differences in hippocampal volume predict verbal and spatial memory performance in patients with Alzheimer's disease , 2000, Hippocampus.

[86]  C. Jack,et al.  Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease , 1998, Neurology.

[87]  J. Kaye,et al.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.

[88]  M. Hallett.  Human Brain Function , 1998, Trends in Neurosciences.

[89]  Alan C. Evans,et al.  A nonparametric method for automatic correction of intensity nonuniformity in MRI data , 1998, IEEE Transactions on Medical Imaging.

[90]  C. Jack,et al.  Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease , 1997, Neurology.

[91]  J. Wegiel,et al.  Relationships between Regional Neuronal Loss and Neurofibrillary Changes in the Hippocampal Formation and Duration and Severity of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[92]  Yoav Freund,et al.  A decision-theoretic generalization of on-line learning and an application to boosting , 1997, EuroCOLT.

[93]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[94]  J. Wegiel,et al.  Atrophy of hippocampal formation subdivisions correlates with stage and duration of Alzheimer disease. , 1995, Dementia.

[95]  D. Collins,et al.  Automatic 3D Intersubject Registration of MR Volumetric Data in Standardized Talairach Space , 1994, Journal of computer assisted tomography.

[96]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[97]  C. Reynolds,et al.  Wechsler memory scale-revised , 1988 .

[98]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[99]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.